Back to top
more

Veeva Systems (VEEV)

(Delayed Data from NYSE)

$282.65 USD

282.65
778,378

+1.19 (0.42%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $282.65 0.00 (0.00%) 7:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Baxter's (BAX) ALTAPORE Bioactive Bone Graft Gets FDA Nod

by Zacks Equity Research

Baxter's (BAX) offers a broad spectrum of surgical products, including bone grafts and substitutes that see lucrative market prospects.

    Zacks Equity Research

    Accuray's CyberKnife Manages Prostate Cancer Effectively

    by Zacks Equity Research

    Accuray's (ARAY) flagship CyberKnife is the only robotic radiotherapy system.

      Zacks Equity Research

      Here's Why You Should Buy Baxter International (BAX) Now

      by Zacks Equity Research

      Baxter's (BAX) raised guidance for 2018 and a series of approvals make it a promising investment pick.

        Zacks Equity Research

        RTI Surgical's (RTIX) TETRAfuse Wins Spine Technology Award

        by Zacks Equity Research

        RTI Surgical (RTIX) to receive the Spine Technology Award from Orthopedics This Week at the NASS 33rd Annual Meeting in Los Angeles.

          Zacks Equity Research

          Boston Scientific Thrives in Urology on New LithoVue Empower

          by Zacks Equity Research

          Boston Scientific's (BSX) combination of LithoVue Empower and LithoVue Single-Use Digital Ureteroscope will put the whole stone manipulation procedure in the operating surgeon's hands.

            Zacks Equity Research

            Quest Diagnostics Grows in Fertility Services With New Buyout

            by Zacks Equity Research

            Quest Diagnostics' (DGX) acquisition of ReproSource lies in tandem with the company's accelerated growth strategy, especially in advanced diagnostics.

              Zacks Equity Research

              Abiomed's Impella Ensures Higher Survival Rates, Shares Up

              by Zacks Equity Research

              Abiomed's (ABMD) Impella successfully treats patients with cardiogenic shocks; market prospects bright.

                Zacks Equity Research

                Here's Why You Should Invest in PRA Health (PRAH) Stock Now

                by Zacks Equity Research

                The CRO industry's bullish prospects currently make PRA Health (PRAH) a promising investment pick.

                  Zacks Equity Research

                  TransEnterix's MST Medical Buyout to Boost Senhance Platform

                  by Zacks Equity Research

                  TransEnterix (TRXC) acquires Israel-based MST Medical, which will boost surgeons' effectiveness and make procedures quick and error-free.

                    Zacks Equity Research

                    Veeva (VEEV) Up 16.1% Since Last Earnings Report: Can It Continue?

                    by Zacks Equity Research

                    Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Zacks Equity Research

                      Here's Why You Should Buy Intuitive Surgical (ISRG) Now

                      by Zacks Equity Research

                      Strength in the surgical platform and a string of developments make Intuitive Surgical (ISRG) a promising pick.

                        Zacks Equity Research

                        Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now

                        by Zacks Equity Research

                        Becton, Dickinson (BD) is likely to gain from expansion into emerging overseas markets.

                          Zacks Equity Research

                          Abbott Banks on New Approvals and Buyouts, Competition Rife

                          by Zacks Equity Research

                          Abbott's (ABT) receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement approval in Japan for the same device will help it revive the dull Vascular business.

                            Sreyoshi Mukherjee headshot

                            3 Top Stocks From the Booming US Medical Products Industry

                            by Sreyoshi Mukherjee

                            The U.S. Medical Products industry is sturdy on solid focus on technological advancement.

                              Zacks Equity Research

                              Cerner Integrated Platform Implemented by Spectrum Health

                              by Zacks Equity Research

                              Spectrum Health selects Cerner's (CERN) Cerner Integrated Platform to treat psychological disorders.

                                Zacks Equity Research

                                Here's Why You Should Hold AngioDynamics' (ANGO) Stock Now

                                by Zacks Equity Research

                                AngioDynamics (ANGO) to benefit from a solid product portfolio. However, the company???s core Peripheral Vascular business has been sluggish.

                                  Zacks Equity Research

                                  Veeva's Vault CDMS to Unify Clinical Data in Single Platform

                                  by Zacks Equity Research

                                  Veeva's (VEEV) cloud-based applications' market prospects bright.

                                    Zacks Equity Research

                                    Here's Why You Should Invest in Masimo (MASI) Right Now

                                    by Zacks Equity Research

                                    A raised guidance for 2018 and positive developments make Masimo (MASI) a lucrative choice for investors.

                                      Zacks Equity Research

                                      Is Veeva Systems (VEEV) Outperforming Other Computer and Technology Stocks This Year?

                                      by Zacks Equity Research

                                      Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?

                                        Zacks Equity Research

                                        Veeva Gains as MD&D Companies Pick Its Cloud-Based Services

                                        by Zacks Equity Research

                                        Veeva's (VEEV) focus on cloud-based services is likely to open up substantial opportunities for the company.

                                          Nabaparna Bhattacharya headshot

                                          3 Cloud-Powered MedTech Stocks to Buy Right Now

                                          by Nabaparna Bhattacharya

                                          Here we take a look at three MedTech companies that are likely to make big business banking on cloud technologies.

                                            Zacks Equity Research

                                            Earnings Estimates Moving Higher for Veeva Systems (VEEV): Time to Buy?

                                            by Zacks Equity Research

                                            Veeva Systems (VEEV) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

                                              Zacks Equity Research

                                              Here's Why You Should Invest in Veeva (VEEV) Stock Right Now

                                              by Zacks Equity Research

                                              Strong fundamentals and a solid Q2 aid Veeva (VEEV).

                                                Zacks Equity Research

                                                Is Veeva Systems (VEEV) Stock Outpacing Its Computer and Technology Peers This Year?

                                                by Zacks Equity Research

                                                Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?

                                                  Zacks Equity Research

                                                  Time to Focus on Veeva Systems (VEEV) for Strong Earnings Growth Potential

                                                  by Zacks Equity Research

                                                  Veeva Systems (VEEV) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.